Journal: Genome Biology
Article Title: O-GlcNAcylation of NONO mediates alternative splicing of SETMAR and facilitates NHEJ repair
doi: 10.1186/s13059-026-03930-5
Figure Lengend Snippet: O-GlcNAcylation enhances the stability of NONO protein. A Left panel: O-GlcNAcylation promotes NONO recruitment to DNA damage sites. U2OS cells expressing GFP-NONO were subjected to laser microirradiation, with or without OSMI-1 treatment. Scale bar: 5 μm. Right panel: Quantification of GFP-NONO intensity at laser-induced damage sites. The intensity of GFP-NONO at laser stripes was quantified at indicated time points using Image J, and peak fluorescence density in the micro-irradiated areas was plotted against time. B Left panel: Inhibition of O-GlcNAcylation reduces NONO binding to chromatin. HEK293T cells were transfected with SFB-NONO and treated with either DMSO or 20 μM OSMI-1 for 48 h. Whole cell extract (WCE), non-chromatin, and chromatin fractions of cells were harvested and analyzed by immunoblotting with the indicated antibodies. Right panel: Quantification of Flag (NONO) level, normalized to histone H3 levels in chromatin and presented as fold change relative to control samples ( n = 3 per condition). C Left panel: Time-dependent degradation of NONO upon OGT inhibition. HEK293T cells were treated with 20 μM OSMI-1 or mock treatment for up to 72 h. NONO protein levels were assessed using Western blot, with GAPDH serving as the loading control. Right panel: Quantification of NONO level, normalized to GAPDH levels and presented as fold change relative to control samples ( n = 3 per condition). D Left panel: Inhibition of O-GlcNAcylation accelerates NONO degradation. HEK293T cells were treated with either DMSO or 20 μM OSMI-1 for 48 h, followed by 50 μM CHX treatment for up to 8 h. NONO protein levels were monitored using Western blot analysis, with GAPDH as the loading control. Right panel: Quantification of NONO level, normalized to GAPDH and presented as fold change relative to control samples ( n = 3 per condition)
Article Snippet: Antibodies used in this study include the following: Anti-DDDDK-tag mAb (MBL, M185-3L), Anti-Myc-tag mAb (MBL, M047-3), Anti-GAPDH (Proteintech, 60,004–1-Ig), OGT polyclonal antibody (Proteintech, 11,576–2-AP), NONO polyclonal antibody (Proteintech, 11,058–1-AP), RL2 (Santa cruz biotechnology, SC-59624, which is an antibody against O-GlcNAc), Histone-H3 polyclonal antibody (Proteintech, 17,168–1-AP), anti-HA (Sigma, 66,006–2-Ig), Anti-PAR monoclonal antibody (R&D, 4335-MC-100-AC), Ku80 polyclonal antibody (Proteintech, 16,389–1-AP), SFPQ polyclonal antibody (Proteintech, 15,585–1-AP), anti-Histone H3(di-methyl K36) polyclonal antibody (abcam, AB9049), Ku70 polyclonal antibody (Proteintech, 10,723–1-AP), anti-SETMAR polyclonal antibody (abcam, ab129455), anti-RAD51 monoclonal antibody(abcam, ab133534).
Techniques: Expressing, Fluorescence, Irradiation, Inhibition, Binding Assay, Transfection, Western Blot, Control